Disability

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the...

Theranica Brings First-in-Class, Drug-Free Migraine Care to the Forefront at CNS 2025 with Product Theater and New Real-World Evidence

With a dedicated product theater and new real-world evidence posters, Theranica will spotlight how the Nerivio® REN wearable is reshaping...

Remedy Robotics Debuts Pioneering Endovascular Surgical Robotic System and Completes World’s First Fully Remote Neurointerventional Procedures

Groundbreaking remotely operable robotic system to transform intervention for stroke and cardiovascular disease, while radically expanding access to care for...

Clario and the University of Oxford’s NeuroMetrology Lab Advance Parkinson’s Disease Research with the Opal® Wearable Sensor System

Clario partners with the University of Oxford's NeuroMetrology Lab to transform Parkinson's disease research with the Opal® wearable sensor system. Partnership...

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic...

MDisrupt Welcomes American Heart Association Professional Members to Its Platform, Unlocking Faster Innovation in Heart and Brain Health

The addition of cardiology and neurology experts helps health companies scale evidence-based health products with confidence AUSTIN, Texas, Sept. 25,...

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active...

error: Content is protected !!